About P2X purinoceptor 1
P2X purinoceptor 1 (P2RX1) is a protein
from Homo sapiens identified by UniProt accession
P51575, 399 residues long.
MolForge cross-references it against 0 known binders and
191 disease associations.
Target properties
| Protein name | P2X purinoceptor 1 |
|---|
| UniProt accession | P51575 |
|---|
| Gene | P2RX1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 399 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (191)
Diseases linked to this target (Open Targets).
- platelet count · score 0.38
- mean platelet volume · score 0.36
- platelet crit · score 0.17
- eosinophil count · score 0.13
- platelet-type bleeding disorder 8 · score 0.11
- cutaneous melanoma · score 0.10
- azoospermia · score 0.09
- colitis · score 0.08
- acute myeloid leukemia · score 0.08
- alkaline phosphatase measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P51575-F1 | alphafold | PREDICTED | 87.82 | — |
Amino-acid sequence (399 residues)
MARRFQEELA AFLFEYDTPR MVLVRNKKVG VIFRLIQLVV LVYVIGWVFL YEKGYQTSSG LISSVSVKLK GLAVTQLPGL GPQVWDVADY VFPAQGDNSF VVMTNFIVTP KQTQGYCAEH PEGGICKEDS GCTPGKAKRK AQGIRTGKCV AFNDTVKTCE IFGWCPVEVD DDIPRPALLR EAENFTLFIK NSISFPRFKV NRRNLVEEVN AAHMKTCLFH KTLHPLCPVF QLGYVVQESG QNFSTLAEKG GVVGITIDWH CDLDWHVRHC RPIYEFHGLY EEKNLSPGFN FRFARHFVEN GTNYRHLFKV FGIRFDILVD GKAGKFDIIP TMTTIGSGIG IFGVATVLCD LLLLHILPKR HYYKQKKFKY AEDMGPGAAE RDLAATSSTL GLQENMRTS
Explore P2X purinoceptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets